AUNA

AI MemoPost-earnings T+3

Auna

As of 2026-08-21/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-21 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Mixed 2Q26 print reset the thesis • 2026-08-18

Base target: $6 / p=50% prob

Biggest risk

The earnings follow-up is more cautious than the prior positive baseline: EBITDA declined despite strong revenue growth, net income fell sharply, and Peru billing penalties plus Mexico and Colombia cost pressure may persist. The stock's sharp initial premarket decline reflected skepticism about the margin recovery.

Invalidation

Break below $4 or thesis failure.

What would change my mind?

Revenue growth, improving cash generation, stable oncology MLR, higher procedures and 3.6x leverage support a recovery case if Mexico and Colombia margins normalize. The company also reaffirmed its 2026 revenue outlook. [#PR-2026-08-18]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-21

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

H2 margin recovery and reaffirmed guidance
Revenue growth, improving cash generation, stable oncology MLR, higher procedures and 3.6x leverage support a recovery case if Mexico and Colombia margins normalize.
The company also reaffirmed its 2026 revenue outlook.

BearKey bullets

Adjusted EBITDA declined 9% FX-neutral and margin fell to 18.4%, with service mix, pharmacy, payroll, talent investment and Peru billing penalties weighing on profitability.
[#PR-2026-08-18]
Coverage is low, analyst target count is unavailable, and no post-print analyst estimate or target revisions were verified.

WatchKey bullets

Mixed 2Q26 print reset the thesis

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $6 (p=50%)

Target spread vs base: +29% / -28%

Scenario probabilities

Bull Target: $8 (p=20%)Base Target: $6 (p=50%)Bear Target: $4 (p=30%)

Commentary

The post-earnings tone is mixed-to-negative: revenue and cash flow were strong, but the market focused on the EBITDA decline and margin compression. Secondary coverage reported a roughly 13%-14% premarket decline followed by substantial recovery; the $5.25 August 20 anchor remained below the prior session's close. Analyst revision evidence is unavailable, so the signal remains a low-coverage monitoring view rather than a confirmed rerating thesis.

As of 2026-08-21 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

H2 margin recovery and reaffirmed guidance

Scenarios

Bull Target (Scenario probability)

$8 / p=20% prob

Base Target (Scenario probability)

$6 / p=50% prob

Bear Target (Scenario probability)

$4 / p=30% prob

Analysis 2026-08-21 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-18
Mixed 2Q26 print reset the thesis
Auna reported 2Q26 revenue of S/1,238 million, up 9% FX-neutral and 13% reported, while Adjusted EBITDA fell 9% FX-neutral to S/227 million and margin was 18.4%. Cash flow and leverage improved, but profitability pressure dominated the initial reaction. [#PR-2026-08-18]
Prob 100.00% • Move -3.30% • Priced-in 85.00%
EVENT2026-09-30
Capacity and clinical-expansion milestones
Auna expects additional Montería capacity to be accretive through the remainder of 2026, a new linear accelerator in Monterrey to become operational in September, and the Versius robotic system to support high-complexity procedures in Peru. Execution and utilization are required before these investments support a rerating. [#PR-2026-08-18]
Prob 60.00% • Move 10.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

H2 margin recovery and reaffirmed guidance
2026-12-31
Management reaffirmed approximately 12% 2026 FX-neutral revenue growth and expects Adjusted EBITDA growth toward the low end of the 10%-14% range, excluding accepted Peru billing penalties. The key test is whether Mexico recovery, Colombia price adjustments and cost normalization convert volume growth into EBITDA. [#PR-2026-08-18]
Prob 48% • Move 18% • Priced-in 45%

Risks

Adjusted EBITDA declined 9% FX-neutral and margin fell to 18.4%, with service mix, pharmacy, payroll, talent investment and Peru billing penalties weighing on profitability. [#PR-2026-08-18]
Coverage is low, analyst target count is unavailable, and no post-print analyst estimate or target revisions were verified.
Currency, payor, regulatory and reimbursement conditions across Mexico, Peru and Colombia could disrupt reported earnings and cash conversion.
Leverage improved to 3.6x but remains above the company's medium-term target below 3.0x. [#PR-2026-08-18]
Management's EBITDA guidance is only toward the low end of the 10%-14% range, increasing execution risk for the second half.

Peers

Symbol	Summary
CYH	Closest healthcare-services framing in the packet, but geography, balance sheet and operating model differ materially; useful only as a loose services-risk reference.
CARL	Similar small-cap sector exposure, but the packet provides no evidence of comparable operations; weak peer for forecasting Auna.
ABT	Large medtech benchmark with substantially different scale and product mix; relevant for broad healthcare sentiment, not direct valuation.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-21

Loading AI feed…

Symbol

Summary

CYH

Closest healthcare-services framing in the packet, but geography, balance sheet and operating model differ materially; useful only as a loose services-risk reference.

CARL

Similar small-cap sector exposure, but the packet provides no evidence of comparable operations; weak peer for forecasting Auna.

ABT

Large medtech benchmark with substantially different scale and product mix; relevant for broad healthcare sentiment, not direct valuation.